The recent surge in capital into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." https://sahilyees734197.affiliatblogger.com/92422360/elite-stakeholder-pharma-hazardous-wager